
Abstracts
Ruthenium polypyridyl complexes are characterized by good thermal stability in the dark but intense optical transitions in the visible part of the spectrum. Depending on the ligands bound to the metal, photon absorption can lead to very different types of excited states with different types of reactivity. In this research seminar, I will drive you to the photochemistry of these molecules and explain how to apply them in biological and biomimetic conditions. On the biological side, we use molecules that deactivate via ligand photocleavage for developing photoactivated chemotherapy (PACT). PACT, like photodynamic therapy (PDT), is a photopharmacological technique aiming to activate anticancer drugs with visible light in order to confine their toxicity to the tumour site and avoid the systemic toxicity of traditional chemotherapy. Unlike the molecules used in PDT, which usually require O₂ to deliver phototoxicity, Ru-based PACT agents are activated by an O₂-independent bond-cleavage reaction. For this reason, we develops them specifically for the treatment of hypoxic (O₂-poor) tumours. On the photocatalytic side, some Ru complexes deactivate via electron transfer to nearby electron acceptors and donor, which opens the door to supramolecular photocatalytic applications. I will showcase this with a few examples of photocatalytic soft interfaces for solar fuels applications.
Financial support by the European Research Council (Starting Grant, Proof-of-Concept grants), EIC (Transition grant), and NWO (VIDI, VICI grants) is gratefully acknowledged.
References:
[1] A. Pannwitz, D. Klein, S. Rodriguez-Jiménez, C. Casadevall, H. Song, E. Reisner,* L. Hammarström,* S. Bonnet, Chem. Soc. Rev. 2021, 50, 4833-4855.
[2] H. Song, A. Amati, A. Pannwitz, S. Bonnet, L. Hammarström, J. Am. Chem. Soc. 2022, 144, 19353-19364.
[3] S. Bonnet, J. Am. Chem. Soc. 2023, 145, 23397–23415.
[4] Y. Husiev, S. K. Gotzfried, M. L. A. Hakkennes, D. Kotova, I. Tutein Nolthenius, C. van de Griend, A. C. Johns, S. Abyar, M. A. Siegler, A. Kornienko, S. Bonnet, J. Am. Chem. Soc. 2025, 147, 44356-44371.
[5] L. Bretin, Y. Husiev, V. Ramu, L. Zhang, M. Hakkennes, S. Abyar, A. C Johns, S. Le Dévédec, T. Betancourt, A. Kornienko, S. Bonnet, Angew. Chem. Int. Ed. 2023, 63, e202316425.
Biography
Sylvestre Bonnet is Full Professor in Bioinorganic Chemistry at Leiden University. He obtained his PhD in 2005 at the University of Strasbourg, France, in the group of Nobel Laureate Jean-Pierre Sauvage. He then moved to The Netherlands as a postdoc, where he improved his experience in homogeneous catalysis, molecular materials, and chemical biology. In 2009 he obtained a Tenure Track at Leiden University, where he was tenured in 2015 and became full professor in 2020. He obtained several prestigious grants, including a Starting Grant from the European Research Council (2013), a Transition grant from the European Innovation Council (2023), and three young investigator grants (VENI 2008, VIDI 2012, VICI 2019) from the Dutch Organisation for Scientific Research (NWO). He is alumni of the Young Academy of Europe, of which he was a board member (2017-2020). His expertise lies at the crossing point between bioinorganic chemistry, photochemistry, and lipid membranes. His current research interests are photoactivated chemotherapy, supramolecular photocatalysis, and upconversion.